J&J announces extension of Abiomed tender offer to December 21

Johnson & Johnson (JNJ) announced that Athos Merger Sub , a wholly owned subsidiary of Johnson & Johnson, has extended to acquire all of the outstanding shares of common stock of Abiomed ( ABMD), for an upfront payment of $380.00 per share in cash, plus one non-tradeable contingent value right entitling the holder to receive up to $35.00 per share in cash if certain commercial and clinical milestones are achieved. The Offer, which was previously scheduled to expire at 11:59 p.m., New York City time, on December 13 has been extended until 11:59 p.m., New York City time, on December 21.